VINCI : Report on payments made by VINCI group subsidiaries to public authorities in respect of their extractive activities

Public limited company (SA) with capital of €1,490,783,277.50
Registered office: 1, cours Ferdinand de Lesseps, 92500 Rueil-Malmaison
Nanterre TCR 552 037 806
www.vinci.com
___________________________________________________

Report
on payments made by VINCI group subsidiaries to
public authorities in respect
of their extractive activities

___________________________________________________

This report, prepared in application of the provisions of article L. 225-102-3 of the Commercial Code, lists the payments made during the 2017 financial year by VINCI group subsidiaries involved in an extractive activity, to the public authorities of each of the States or territories in which they perform their activities.

In compliance with the legal and regulatory provisions, this list includes the amounts of individual payments, or all payments when they are interconnected, equal to or greater than 100,000 euros, made per site, per country and per contribution type, to public authorities during the 2017 financial year. If no payment has been made by a subsidiary or if a subsidiary undertaking the extractive project has only made payments below the threshold of 100,000 euros, these projects or payment types are not included in this report's table.

The taxes and duties primarily include corporate income tax owed for the financial year, as well as taxes related to earnings and the production of the companies undertaking the projects. This report excludes taxes and duties collected on the basis of consumption or sales, such as value added taxes.

The fees and rents represent payments made in exchange for rights required for the exploitation of the quarries.

In 2017, these payments were the following:

This report was approved by the VINCI Board of Directors during its meeting on 19 June 2018.

Drafted in Rueil-Malmaison, on 19 June 2018
Xavier Huillard, Chairman and Chief Executive Officer

Attachment

• PDF.pdf

© 2018 GlobeNewswire, Inc. All Rights Reserved.

Read More..

The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.

BioNTech (Nasdaq: BNTX) and Fosun Pharma Announce Start of Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in China